Analyzing the Role of Tofacitinib in Treatment of Alopecia Areata: A Retrospective Analysis from a Tertiary Care Center of North India

The study evaluated the effectiveness of tofacitinib, a Janus kinase inhibitor, in 17 patients with alopecia areata over a 6-month period at a North Indian tertiary care center. The patients, with a mean age of 27.88 years and a male-to-female ratio of 2.4:1, had been suffering from the condition for an average of 32.29 months. Using the Severity of Alopecia Tool (SALT) score to assess hair loss, the study found a significant reduction in SALT scores (P = 0.0001) after treatment, indicating that tofacitinib was effective. No adverse effects were reported, and all patients completed the study. The research suggests tofacitinib is a promising treatment for alopecia areata, but calls for larger studies to confirm these findings.